Invivyd (IVVD) Competitors $0.69 +0.00 (+0.64%) Closing price 04:00 PM EasternExtended Trading$0.68 0.00 (-0.42%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. BNTC, GOSS, CMPS, PRTA, ALT, AURA, RNAC, CAPR, AMRN, and INBXShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Benitec Biopharma (BNTC), Gossamer Bio (GOSS), COMPASS Pathways (CMPS), Prothena (PRTA), Altimmune (ALT), Aura Biosciences (AURA), Cartesian Therapeutics (RNAC), Capricor Therapeutics (CAPR), Amarin (AMRN), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Its Competitors Benitec Biopharma Gossamer Bio COMPASS Pathways Prothena Altimmune Aura Biosciences Cartesian Therapeutics Capricor Therapeutics Amarin Inhibrx Biosciences Benitec Biopharma (NASDAQ:BNTC) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Is BNTC or IVVD more profitable? Benitec Biopharma has a net margin of 0.00% compared to Invivyd's net margin of -389.01%. Benitec Biopharma's return on equity of -38.26% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Benitec BiopharmaN/A -38.26% -35.71% Invivyd -389.01%-165.24%-99.71% Which has more volatility & risk, BNTC or IVVD? Benitec Biopharma has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Do analysts recommend BNTC or IVVD? Benitec Biopharma currently has a consensus price target of $23.83, indicating a potential upside of 102.84%. Invivyd has a consensus price target of $5.85, indicating a potential upside of 751.65%. Given Invivyd's stronger consensus rating and higher possible upside, analysts clearly believe Invivyd is more favorable than Benitec Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Benitec Biopharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do insiders & institutionals have more ownership in BNTC or IVVD? 52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by company insiders. Comparatively, 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has preferable valuation & earnings, BNTC or IVVD? Benitec Biopharma has higher earnings, but lower revenue than Invivyd. Benitec Biopharma is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBenitec Biopharma$80K3,855.47-$21.75M-$1.51-7.78Invivyd$25.38M3.25-$169.93M-$1.20-0.57 Does the media favor BNTC or IVVD? In the previous week, Benitec Biopharma had 1 more articles in the media than Invivyd. MarketBeat recorded 2 mentions for Benitec Biopharma and 1 mentions for Invivyd. Invivyd's average media sentiment score of 1.87 beat Benitec Biopharma's score of 0.47 indicating that Invivyd is being referred to more favorably in the news media. Company Overall Sentiment Benitec Biopharma Neutral Invivyd Very Positive SummaryInvivyd beats Benitec Biopharma on 9 of the 17 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$81.87M$2.91B$5.52B$9.32BDividend YieldN/A2.46%4.25%4.05%P/E Ratio-0.5720.3628.1519.68Price / Sales3.25302.56437.63100.28Price / CashN/A42.3835.5357.53Price / Book1.237.768.235.67Net Income-$169.93M-$55.11M$3.23B$257.51M7 Day Performance-8.41%0.95%-0.01%0.52%1 Month Performance-12.84%8.44%5.61%8.84%1 Year Performance-50.58%-2.38%26.52%14.18% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.4408 of 5 stars$0.69+0.6%$5.85+751.7%-47.1%$81.87M$25.38M-0.57100Gap UpBNTCBenitec Biopharma1.6031 of 5 stars$13.25+3.7%$23.83+79.9%+22.0%$347.81M$80K-8.7720GOSSGossamer Bio3.7609 of 5 stars$1.53+12.5%$8.25+439.2%+22.9%$347.77M$114.70M-6.65180News CoveragePositive NewsAnalyst ForecastGap UpHigh Trading VolumeCMPSCOMPASS Pathways1.7899 of 5 stars$3.71+1.1%$17.00+358.2%-50.0%$347.11MN/A-1.86120Analyst ForecastAnalyst RevisionPRTAProthena3.5833 of 5 stars$6.43+0.5%$31.50+389.9%-72.5%$346.11M$137.94M-3.09130ALTAltimmune2.1959 of 5 stars$4.26+2.9%$18.20+327.2%-47.1%$345.53M$20K-3.3850AURAAura Biosciences2.5625 of 5 stars$6.75+5.5%$22.00+225.9%-27.0%$339.32MN/A-3.5550RNACCartesian Therapeutics2.2281 of 5 stars$13.06-2.0%$40.00+206.3%-24.2%$338.91M$38.91M-0.2564CAPRCapricor Therapeutics2.5258 of 5 stars$7.39-3.3%$22.56+205.2%+54.1%$337.58M$22.27M-5.20101Analyst ForecastAnalyst RevisionGap DownAMRNAmarin0.2845 of 5 stars$16.10-4.9%$12.00-25.5%+5.1%$333.43M$228.61M-4.42360Positive NewsINBXInhibrx Biosciences2.7527 of 5 stars$22.96+5.5%N/A+65.7%$332.46M$200K0.20166 Related Companies and Tools Related Companies BNTC Competitors GOSS Competitors CMPS Competitors PRTA Competitors ALT Competitors AURA Competitors RNAC Competitors CAPR Competitors AMRN Competitors INBX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
